Recommendations for the treatment of tear trough deformity with cross‐linked hyaluronic acid filler

Anido, Javier; Fernández, José Manuel; Genol, Ignacio; Ribé, Natalia; Sevilla, Gema P

doi:10.1111/jocd.13475

Cited by 39 publications

(56 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There has been an increasing desire to mitigate the cosmetic effects of aging particularly through the eyes which has led to an increased frequency of diagnosis of tear trough deformity and an increase in the number of treatments being performed. 1,2 According to the American Society for Aesthetic Plastic Surgery statistics, in 2020 there were an estimated 1.3 million dermal filler procedures performed nationwide with $996 million in revenue. 3 There are numerous different methods that can be used to lessen the appearance of tear troughs by enhancing volume beneath the eyelids.…”

mentioning

confidence: 99%

Delayed Complications following Dermal Filler for Tear Trough Augmentation: A Systematic Review

Trinh

McGuigan

Gupta³

2021

Facial Plast Surg

View full text Add to dashboard Cite

Tear trough deformity is a popular target for the treatment with filler injections. The side effects are generally mild and transient. However, delayed complications may occur. We aim to perform a thorough systematic review of the published literature related to delayed complications after tear trough filler injections. A search of published literature was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines in June 2021 and included PubMed, ScienceDirect, and Embase databases. The Medical Subject Headings (MeSH) terms used included the following terms: delayed complications, nodules, granulomas, swelling, discoloration, dermal filler, hyaluronic acid (HA), polyacrylamide, calcium hydroxyapatite (CaHA), poly-L-lactic acid (PLLA), eyelid, periorbital, periocular, and tear trough. Twenty-eight articles consisting of 52 individual cases were included in the final analysis. 98% (51/52) of patients were female and had an average age of 48.3 years. HA was the most reported product (71.2%, 37/52), followed by PLLA (4/52, 7.7%), and CaHA (4/52, 7.7%). The most common delayed complication with any dermal filler was swelling (42.3%, 22/52) followed by lumps or nodules (25.0%, 13/52). Xanthelasma-like reaction (17.3%, 9/52), migration (7.7%, 4/52), discoloration (3%, 3/52) also occurred. The average time of onset of any complication was 16.8 months with xanthelasma-like reaction appearing soonest (mean: 10 months) and discoloration appearing latest (mean: 52 months). Most swelling cases were caused by HA. Semi-permanent fillers such as PMMA and synthetic fillers such as PLLA were more likely to be associated with lumps and nodules than other complications. It is important that clinicians who perform tear trough augmentation with dermal fillers have a thorough understanding of the risks of the procedure to diagnose and manage them promptly as well as provide patients with accurate information regarding the potential adverse effects.

show abstract

mentioning

confidence: 99%

Delayed Complications following Dermal Filler for Tear Trough Augmentation: A Systematic Review

Trinh

McGuigan

Gupta³

2021

Facial Plast Surg

View full text Add to dashboard Cite

show abstract

“…Most investigators use either microdroplets, linear threading, or a combination of both along the groove with good results and high patient satisfaction rates. Special attention has to be paid in avoidance of intraorbital injection 6–12 …”

Section: Discussionmentioning

confidence: 99%

“…The deep plane injections reduce the risk of irregularities, accidental vascular injections, and ensure a longer persistence of the warranted effects. [6][7][8][9][10][11][12] Another way is targeting injection points lateral to the line of ligaments. This technique has been shown to reduce the necessary filler amounts.…”

mentioning

confidence: 99%

Correction of tear trough deformity by hyaluronic acid soft tissue filler placement inferior to the lateral orbital thickening

Wollina

Goldman

2021

Dermatologic Therapy

View full text Add to dashboard Cite

Tear trough deformities can be a sign of facial aging and exert a negative impact in facial attractiveness. Surgical techniques and adipose tissue transfer have been used to improve tear trough deformity. In recent years, minimal invasive procedures such as soft tissue filler injections became more popular. We report a retrospective evaluation of 45 Caucasian female patients ≥40 years (mean age of [58.8 ± 8.9] years). Severity of tear trough was classified according to Hirmand: 3 as grade I, 28 as grade II, and 14 grade III tear trough deformities. We used a monophasic hyaluronic acid, low G prime filler placed inferior to the lateral orbital thickening. On average, 0.4 ml of hyaluronic acid (HA) filler were injected per side. The improvement was I grade 29 patients and II grades in 16 patients. The improvement lasted (10.8 ± 2.3) months. No severe adverse events were noted. Vascular danger zones can be avoided.

show abstract

“…Previous literature published a frequency of 11.6% and 0.9% of transient edema or inflammation and severe edema, respectively, following tear trough filler injections independent from vaccination. 6 Therefore, according to the data from this retrospective study and due to the increasing morbidity and mortality of the COVID‐19 pandemic, vaccination should not be discouraged in a patient with previous dermal filler injected tear trough. Furthermore, as more people receive the third dose of the vaccine worldwide, more data will be available regarding the connection, if any, between dermal filler and COVID‐19 vaccine.…”

Section: Tablementioning

confidence: 93%

COVID‐19 vaccine in patients with dermal hyaluronic acid fillers in the tear trough: A retrospective study

Azzam

Hamed

Mukari³

2022

J of Cosmetic Dermatology

View full text Add to dashboard Cite

To the Editor, COVID-19 has affected the entire world since its onset in 2020.Recently, concerns have raised regarding potential hypersensitivity reactions of previously placed HA dermal fillers with COVID-19 vaccines. The Moderna mRNA-1273 vaccine trial reported an incidence rate of facial swelling of 0.02% after receiving the vaccine. 1 We conducted a retrospective study that aimed to assess the incidence of adverse events related to COVID-19 vaccines.All included patients had received two doses of Pfizer/BioNTech COVID-19 vaccine (US) (interval of 21-28 days) and had been previously injected with dermal fillers in the tear trough area, from January 2020 to January 2021. This study adhered to the principles

show abstract

Recommendations for the treatment of tear trough deformity with cross‐linked hyaluronic acid filler

Abstract: This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Cited by 39 publications

References 40 publications

Delayed Complications following Dermal Filler for Tear Trough Augmentation: A Systematic Review

Delayed Complications following Dermal Filler for Tear Trough Augmentation: A Systematic Review

Correction of tear trough deformity by hyaluronic acid soft tissue filler placement inferior to the lateral orbital thickening

COVID‐19 vaccine in patients with dermal hyaluronic acid fillers in the tear trough: A retrospective study

Contact Info

Product

Resources

About